





**PATENT** 

Attorney Docket No.: 03495.0008-09000

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Marc ALIZON et al.	
Serial No.: 08/466,921	) Group Art Unit: 1813
Filed: June 6, 1995	Examiner: Jeffrey S. PARKIN
For: METHOD OF PRODUCING AN IMMUNODEFICIENCY VIRUS	TIBODIES TO ANTIGENS OF HUMAN  TYPE 1 (HIV-1) ECENTICAL
Assistant Commissioner for Patents Washington, D.C. 20231	JUN 4 1997 GROUF 1800
Sir:	*17497 RJOHNSON 00000037 08466924-00 OP

## **RESPONSE TO PAPER NO. 7**

This paper is filed in response to the Final Office Action of July 2, 1996 (Paper No. 7) and the Advisory Action mailed December 4, 1996 (Paper No.10), the period of response to which has been extended by filing a petition for extension of time and fee concurrently herewith. Pursuant to 37 C.F.R. § 1.116, please amend this application as follows:

## IN THE CLAIMS:

Please <u>cancel</u> claims 23-27 and 30-31, <u>amend</u> claim 28, and <u>add</u> claims 32-45 as follows:

28. (Amended) A recombinant vector comprising a DNA fragment as claimed in any one of claims 32 through 45 (234 through 27).

FINNEGAN, HENDERSO FARABOW, GARRETT 8 DUNNER, L. L. P. 1300 I STREET, N. W. ASHINGTON, D. C. 20005 202-408-4000

32. A purified DNA fragment of HIV 1 having a BamHI site at approximately 8150 and affects site at approximately 9150, wherein the DNA fragment consists of a restriction fragment

generated by the BamHI site at approximately 8150 to the BgIII site at approximately 9150.